Omadacycline for Community-Acquired Bacterial Pneumonia

Stets, Roman; Popescu, Monica; Gonong, Joven; Mitha, Ismail; Nseir, William; Madej, Andrzej; Kirsch, Courtney; Das, Anita; Garrity-Ryan, Lynne; Steenbergen, Judith N.; Manley, Amy; Eckburg, Paul B.; Tzanis, Evan; McGovern, Paul C.; Loh, Evan

doi:10.1056/nejmoa1800201

Cited by 162 publications

(180 citation statements)

References 27 publications

Supporting

Mentioning

162

Contrasting

Unclassified

Order By: Relevance

“…The current study results indicate that omadacycline demonstrates relative intracellular penetrance against L. pneumophila serogroup 1, comparable to other antibiotics used for CABP treatment. Findings also support those from a phase 3 study of CABP in which omadacycline was comparable to moxifloxacin, with a 87% early clinical success rate among 37 patients for whom L. pneumophila was identified as the causative pathogen (25). Thus, omadacycline may be a potential option for empirical therapy for CABP, particularly when atypical bacteria, especially L. pneumophila, are suspected.…”

supporting

confidence: 76%

In Vitro and Intracellular Activities of Omadacycline against Legionella pneumophila

Dubois

Martel

2020

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Omadacycline is an aminomethylcycline antibiotic with in vitro activity against pathogens causing community-acquired bacterial pneumonia (CABP). This study investigated the activity of omadacycline against Legionella pneumophila strains isolated between 1995 and 2014 from nosocomial or community-acquired respiratory infections. Omadacycline exhibited extracellular activity similar to comparator antibiotics; intracellular penetrance was found by day 3 of omadacycline exposure. These results support the utility of omadacycline as an effective antibiotic for the treatment of CABP caused by L. pneumophila.

show abstract

supporting

confidence: 76%

In Vitro and Intracellular Activities of Omadacycline against Legionella pneumophila

Dubois

Martel

2020

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…However, new antibiotics were often being developed to improve their activity against several MDR microorganisms, which are, as previously shown, uncommon in CAP. Most of these trials focused on patients with non-severe CAP requiring hospitalization [62][63][64][65][66][67][68], excluding severely ill patients (or ICU patients), so recommendations for these groups of patients are Could PK/PD interventions change the outcomes in severe CAP?…”

Section: Antibiotic Therapymentioning

confidence: 99%

Burden of Community-Acquired Pneumonia and Unmet Clinical Needs

2020

View full text Add to dashboard Cite

Community-acquired pneumonia (CAP) is the leading cause of death among infectious diseases and an important health problem, having considerable implications for healthcare systems worldwide. Despite important advances in prevention through vaccines, new rapid diagnostic tests and antibiotics, CAP management still has significant drawbacks. Mortality remains very high in severely ill patients presenting with respiratory failure or shock but is Enhanced Digital Features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.11673588. J. Ferreira-Coimbra (

show abstract

“…Additionally, 220 studies were found to be irrelevant after screening the title and abstract (based on the article type and language) and 15 studies after screening the full text. Eventually, eight RCTs [11][12][13][14][15][16][17][18] were selected for the meta-analysis ( Figure 1).…”

Section: Study Selectionmentioning

confidence: 99%

“…All eight included RCTs [11][12][13][14][15][16][17][18] were multicenter studies ( Table 1). Each four studies used omadacycline [12,13,17,18] and eravacycline [11,[14][15][16] as the study drug.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Furthermore, they exhibit potent in vitro activity against multidrug-resistant organisms [9,10]. The clinical efficacy of omadacycline and eravacycline for treating acute bacterial infections is being evaluated in several randomized controlled trials (RCTs) since their development [11][12][13][14][15][16][17][18]. However, no consensus on the efficacy and safety of novel tetracyclines has been reached due to the lack of a systematic analysis and an updated meta-analysis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Novel Tetracyclines Versus Alternative Antibiotics for Treating Acute Bacterial Infection: A Meta-Analysis of Randomized Controlled Trials

Lan

Lin

Chang³

et al. 2019

Antibiotics

View full text Add to dashboard Cite

This meta-analysis assessed the efficacy and safety of novel tetracyclines for treating acute bacterial infections. Data from PubMed, Web of Science, EBSCO, Cochrane databases, Ovid Medline, and Embase databases were accessed until 11 July 2019. Only randomized controlled trials (RCTs) comparing the efficacy of novel tetracyclines with that of other antibiotics for treating acute bacterial infections were included. Primary outcomes included the clinical response, microbiological response, and risk of adverse events (AEs). A total of eight RCTs were included, involving 2283 and 2197 patients who received novel tetracyclines and comparators, respectively. Overall, no significant difference was observed in the clinical response rate at test of cure between the experimental and control groups (for modified intent-to-treat [MITT] population, risk ratio [RR]: 1.02, 95% confidence interval [CI]: 0.99–1.05; for clinically evaluable [CE] population, RR: 1.02, 95% CI: 1.00–1.04; and for microbiological evaluable [ME] population, RR: 1.01, 95% CI: 0.99–1.04). No significant difference in the microbiological response at the end of treatment was observed between the experimental and control groups (for ME population, RR: 1.01, 95% CI: 0.99–1.03; for microbiological MITT population, RR: 1.01, 95% CI: 0.96–1.07). No difference was observed concerning the risk of treatment-emergent adverse events (TEAEs), serious adverse events, and discontinuation of treatment due to TEAEs and all-cause mortality between the two groups. In conclusion, clinical efficacy and safety profile for novel tetracyclines in the treatment of acute bacterial infections were found to be similar to those for other available antibiotics.

show abstract

Omadacycline for Community-Acquired Bacterial Pneumonia

Cited by 162 publications

References 27 publications

In Vitro and Intracellular Activities of Omadacycline against Legionella pneumophila

In Vitro and Intracellular Activities of Omadacycline against Legionella pneumophila

Burden of Community-Acquired Pneumonia and Unmet Clinical Needs

Novel Tetracyclines Versus Alternative Antibiotics for Treating Acute Bacterial Infection: A Meta-Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About